Atopic dermatitis differential diagnosis: Difference between revisions
Jump to navigation
Jump to search
Line 14: | Line 14: | ||
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Inherited | ! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Inherited | ||
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquired | ! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquired | ||
! colspan=" | ! colspan="11" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Clinical manifestations | ||
| rowspan="5" |Associated Factors | |||
! colspan="4" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings | ! colspan="4" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings | ||
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings | ! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings | ||
|- | |- | ||
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Demography | ! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Demography | ||
! colspan="6" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Symptoms | ! colspan="6" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Symptoms | ||
! colspan="4" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical examination | ! colspan="4" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical examination | ||
Line 53: | Line 53: | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Incidence is highest during infancy and early childhood. | * Incidence is highest during infancy and early childhood. | ||
| align="center" style="background:#F5F5F5;" | Multiple | | align="center" style="background:#F5F5F5;" | Multiple | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 83: | Line 79: | ||
* White dermographism | * White dermographism | ||
* Perifollicular accentuation | * Perifollicular accentuation | ||
| align="center" style="background:#F5F5F5;" | | |||
* Family history of atopic dermatitis or other [[atopy]] | |||
* Personal history of [[atopy]] ([[asthma]], [[allergic rhinitis]], [[food allergy]]) | |||
* Active and passive exposure to tobacco | |||
| align="center" style="background:#F5F5F5;" | Nl to ↑ | | align="center" style="background:#F5F5F5;" | Nl to ↑ | ||
Line 106: | Line 106: | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" |Any | | align="center" style="background:#F5F5F5;" |Any | ||
| align="center" style="background:#F5F5F5;" |May be multiple after 1-2 days of exposure | | align="center" style="background:#F5F5F5;" |May be multiple after 1-2 days of exposure | ||
| align="center" style="background:#F5F5F5;" | Erythematous well-demarcated papules | | align="center" style="background:#F5F5F5;" | Erythematous well-demarcated papules | ||
Line 122: | Line 119: | ||
* Localized swelling | * Localized swelling | ||
* Lichenified pruritic plaques | * Lichenified pruritic plaques | ||
| align="center" style="background:#F5F5F5;" | | |||
* Contact with allergens in the past 1-2 days | |||
* Positive family history | |||
| align="center" style="background:#F5F5F5;" |Nl to ↑ | | align="center" style="background:#F5F5F5;" |Nl to ↑ | ||
(Eosinophilia) | (Eosinophilia) | ||
Line 136: | Line 136: | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" |Any, more occupational exposure | | align="center" style="background:#F5F5F5;" |Any, more occupational exposure | ||
| align="center" style="background:#F5F5F5;" |Usually single immediately after the exposure | | align="center" style="background:#F5F5F5;" |Usually single immediately after the exposure | ||
| align="center" style="background:#F5F5F5;" | Well-demarcated red patch with a glazed surface | | align="center" style="background:#F5F5F5;" | Well-demarcated red patch with a glazed surface | ||
Line 151: | Line 149: | ||
* Dryness | * Dryness | ||
* Thicker skin | * Thicker skin | ||
| align="center" style="background:#F5F5F5;" | | |||
* Cumulative exposure to irritants | |||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
Line 167: | Line 167: | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | Any, onset during the 1st days or weeks of life | | align="center" style="background:#F5F5F5;" | Any, onset during the 1st days or weeks of life | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | Greasy scaling on a yellow-red base | | align="center" style="background:#F5F5F5;" | Greasy scaling on a yellow-red base | ||
Line 181: | Line 177: | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | |||
* Stress | |||
* Cold, dry weather | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 194: | Line 194: | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | Any, 2 peaks of onset 30-39 years and 50-59 years | | align="center" style="background:#F5F5F5;" | Any, 2 peaks of onset 30-39 years and 50-59 years | ||
| align="center" style="background:#F5F5F5;" | Multiple | | align="center" style="background:#F5F5F5;" | Multiple | ||
| align="center" style="background:#F5F5F5;" | Well-circumscribed, pink papules and symmetrically distributed cutaneous plaques with silvery scales | | align="center" style="background:#F5F5F5;" | Well-circumscribed, pink papules and symmetrically distributed cutaneous plaques with silvery scales | ||
Line 220: | Line 212: | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | |||
* Smoking | |||
* Skin trauma | |||
* Alcohol abuse | |||
* Stress | |||
* Cold weather | |||
* Vitamin D deficiency | |||
* Drugs | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 232: | Line 232: | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | Any, peak at 30-50 years of age | | align="center" style="background:#F5F5F5;" | Any, peak at 30-50 years of age | ||
| align="center" style="background:#F5F5F5;" | Multiple | | align="center" style="background:#F5F5F5;" | Multiple | ||
| align="center" style="background:#F5F5F5;" | Lichenified and erythematous, pruritic exudative plaque, and excoriations | | align="center" style="background:#F5F5F5;" | Lichenified and erythematous, pruritic exudative plaque, and excoriations | ||
Line 250: | Line 244: | ||
* Color of plaque varies fro, yellow to reddish brown | * Color of plaque varies fro, yellow to reddish brown | ||
* Plaque size can vary between 3X6 cm 6X10 cm areas. | * Plaque size can vary between 3X6 cm 6X10 cm areas. | ||
| align="center" style="background:#F5F5F5;" | | |||
* Emotional stress | |||
* Sleep disturbances | |||
* Dry weather | |||
* Sweating | |||
* Excessive dryness | |||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
Line 271: | Line 271: | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | Usually in infancy | | align="center" style="background:#F5F5F5;" | Usually in infancy | ||
| align="center" style="background:#F5F5F5;" | Multiple | | align="center" style="background:#F5F5F5;" | Multiple | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 291: | Line 288: | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Scales can vary from mild scaling to large, plate (armor)-like scales and thickening of the skin. | * Scales can vary from mild scaling to large, plate (armor)-like scales and thickening of the skin. | ||
| align="center" style="background:#F5F5F5;" | | |||
* Dry and cold weather | |||
* Increased risk of atopic diseases including asthma, alllergic rhinitis and atopic dermatitis | |||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
Line 307: | Line 307: | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | Any, two peaks, 6th-7th decade of life in males and 2nd-3rd decade of life in females | | align="center" style="background:#F5F5F5;" | Any, two peaks, 6th-7th decade of life in males and 2nd-3rd decade of life in females | ||
| align="center" style="background:#F5F5F5;" | Multiple | | align="center" style="background:#F5F5F5;" | Multiple | ||
| align="center" style="background:#F5F5F5;" |Nl | | align="center" style="background:#F5F5F5;" |Nl | ||
Line 328: | Line 321: | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Chronically lesions result into central clearing leading to annular lesions. | * Chronically lesions result into central clearing leading to annular lesions. | ||
| align="center" style="background:#F5F5F5;" | | |||
* Temperature changes (particularly winter) | |||
* Emotional stress | |||
* Dry skin | |||
* Environmental irritants | |||
* Recent surgery | |||
* Medications like topical antibiotic creams and isotretinoin | |||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
Line 343: | Line 343: | ||
| align="center" style="background:#F5F5F5;" | – | | align="center" style="background:#F5F5F5;" | – | ||
| align="center" style="background:#F5F5F5;" | Affects neonates | | align="center" style="background:#F5F5F5;" | Affects neonates | ||
| align="center" style="background:#F5F5F5;" | Multiple | | align="center" style="background:#F5F5F5;" | Multiple | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 371: | Line 369: | ||
** "Bamboo hair" or "ball and socket deformity" of hair and eyebrows | ** "Bamboo hair" or "ball and socket deformity" of hair and eyebrows | ||
** Nodes along the hair shaft | ** Nodes along the hair shaft | ||
| align="center" style="background:#F5F5F5;" | | |||
* Atopic diseases including food allergy and strong family history of asthma, atopic dermatitis and allergic rhinitis | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* ↑ serum immunoglobulin E (IgE) levels | * ↑ serum immunoglobulin E (IgE) levels | ||
Line 392: | Line 392: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquired | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquired | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Demography | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Demography | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Single/ | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Single/ | ||
Multiple | Multiple | ||
Line 404: | Line 403: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Tenderness | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Tenderness | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated factors | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |WBC | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |WBC | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelets | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelets | ||
Line 504: | Line 504: | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | Any, peak among children >5 years of age and young adults | | align="center" style="background:#F5F5F5;" | Any, peak among children >5 years of age and young adults | ||
| align="center" style="background:#F5F5F5;" | Multiple | | align="center" style="background:#F5F5F5;" | Multiple | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 522: | Line 517: | ||
| align="center" style="background:#F5F5F5;" | – | | align="center" style="background:#F5F5F5;" | – | ||
| align="center" style="background:#F5F5F5;" | If molluscum contagiosum is acquired as sexually transmitted disease, it involves, groin and genital region. | | align="center" style="background:#F5F5F5;" | If molluscum contagiosum is acquired as sexually transmitted disease, it involves, groin and genital region. | ||
| align="center" style="background:#F5F5F5;" | | |||
* Often asymptomatic | |||
* Tender or pruritic skin lesions | |||
* Self resolve within 2 months | |||
* Immunocompetent patients present with extensive and severe infections | |||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
Line 537: | Line 537: | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" |Multiple | | align="center" style="background:#F5F5F5;" |Multiple | ||
| align="center" style="background:#F5F5F5;" | Erythematous papular lesions | | align="center" style="background:#F5F5F5;" | Erythematous papular lesions | ||
Line 549: | Line 547: | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | |||
* Positive family history | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 582: | Line 582: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquired | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquired | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Demography | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Demography | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Single/ | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Single/ | ||
Multiple | Multiple | ||
Line 594: | Line 593: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Tenderness | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Tenderness | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated factors | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |WBC | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |WBC | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelets | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelets | ||
Line 606: | Line 606: | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | Any, mean age of disease onset is 2nd-4th decade | | align="center" style="background:#F5F5F5;" | Any, mean age of disease onset is 2nd-4th decade | ||
| align="center" style="background:#F5F5F5;" | Multiple | | align="center" style="background:#F5F5F5;" | Multiple | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 624: | Line 621: | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Oral manifestation such as vesicles and erosion may be present | * Oral manifestation such as vesicles and erosion may be present | ||
| align="center" style="background:#F5F5F5;" | | |||
* Intermittent pruritic papules and vesicles | |||
* Associated small intestine celiac disease with villous atrophy and crypt hyperplasia | |||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
Line 642: | Line 642: | ||
| align="center" style="background:#F5F5F5;" | – | | align="center" style="background:#F5F5F5;" | – | ||
| align="center" style="background:#F5F5F5;" | Seen almost exclusively in males in infancy | | align="center" style="background:#F5F5F5;" | Seen almost exclusively in males in infancy | ||
| align="center" style="background:#F5F5F5;" | Multiple | | align="center" style="background:#F5F5F5;" | Multiple | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 665: | Line 658: | ||
| align="center" style="background:#F5F5F5;" | – | | align="center" style="background:#F5F5F5;" | – | ||
| align="center" style="background:#F5F5F5;" | Infants can present with petechiae, prolonged bleeding from umbilicus or circumcision, purpura, hematemesis, melena, epistaxis, hematuria or unusal bruising | | align="center" style="background:#F5F5F5;" | Infants can present with petechiae, prolonged bleeding from umbilicus or circumcision, purpura, hematemesis, melena, epistaxis, hematuria or unusal bruising | ||
| align="center" style="background:#F5F5F5;" | | |||
* Blleeding: severe thrombocytopenia, | |||
* Eczema - similar to atopic dermatitis | |||
* Recurrent sino-pulmonary infections | |||
* Opportunistic infections. | |||
* Autoimmune diseases | |||
* Malignancies | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* ↑ Eosinophilia | * ↑ Eosinophilia | ||
Line 686: | Line 686: | ||
| align="center" style="background:#F5F5F5;" | – | | align="center" style="background:#F5F5F5;" | – | ||
| align="center" style="background:#F5F5F5;" | Rare, begin in infancy | | align="center" style="background:#F5F5F5;" | Rare, begin in infancy | ||
| align="center" style="background:#F5F5F5;" | Multiple | | align="center" style="background:#F5F5F5;" | Multiple | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 717: | Line 708: | ||
* High-arched oral palate | * High-arched oral palate | ||
* Hyperextensible joints | * Hyperextensible joints | ||
| align="center" style="background:#F5F5F5;" | | |||
* Cold abscesses | |||
* Pruritic eczema | |||
* Allergic diseases | |||
* Noneruption of permanent teeth | |||
* Multiple bone fractures and scoliosisis | |||
* Peripheral T-cell lymphoma | |||
* Coronary artery aneurysms | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* ↑ Eosinophilia | * ↑ Eosinophilia | ||
Line 797: | Line 797: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquired | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquired | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Demography | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Demography | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Single/ | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Single/ | ||
Multiple | Multiple | ||
Line 809: | Line 808: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Tenderness | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Tenderness | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated factors | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |WBC | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |WBC | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelets | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelets | ||
Line 999: | Line 999: | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | Mean age is 55- 60 years | | align="center" style="background:#F5F5F5;" | Mean age is 55- 60 years | ||
| align="center" style="background:#F5F5F5;" | Multiple | | align="center" style="background:#F5F5F5;" | Multiple | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | – | ||
| align="center" style="background:#F5F5F5;" | + | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 1,067: | Line 1,067: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquired | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquired | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Demography | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Demography | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Single/ | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Single/ | ||
Multiple | Multiple | ||
Line 1,079: | Line 1,078: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Tenderness | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Tenderness | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated factors | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |WBC | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |WBC | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelets | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelets | ||
Line 1,095: | Line 1,095: | ||
[[Category:Primary care]] | [[Category:Primary care]] | ||
{{WikiDoc Help Menu}} | +{{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} |
Revision as of 22:01, 24 October 2018
Atopic dermatitis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Atopic dermatitis differential diagnosis On the Web |
American Roentgen Ray Society Images of Atopic dermatitis differential diagnosis |
Risk calculators and risk factors forAtopic dermatitis differential diagnosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
Differentiating Atopic Dermatitis from other Diseases
Category | Diseases | Etiology | Inherited | Acquired | Clinical manifestations | Associated Factors | Para-clinical findings | Additional findings | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Demography | Symptoms | Physical examination | |||||||||||||||||||
Lab Findings | Histopathology | ||||||||||||||||||||
Appearance | Itching | Bleeding | Fever | BP | Tenderness | Other | CBC | ESR/CRP | |||||||||||||
Single/
Multiple |
Rash | Involved areas | Pustule | WBC | Platelets | ||||||||||||||||
Skin disorders | Atopic dermatitis |
|
+ | + |
|
Multiple |
|
– | + | – | – | NA | – |
|
|
Nl to ↑
(Eosinophilia) |
Nl | Nl |
|
| |
Allergic contact dermatitis[1] |
|
– | + | Any | May be multiple after 1-2 days of exposure | Erythematous well-demarcated papules | Surrounding the area in contact with the offending agent | – | + | – | – | Nl | + |
|
|
Nl to ↑
(Eosinophilia) |
Nl | Nl | NA |
| |
Irritant contact dermatitis[2] |
|
– | + | Any, more occupational exposure | Usually single immediately after the exposure | Well-demarcated red patch with a glazed surface | Any area in contact with the irritant | – | + | – | – | Nl | + |
|
|
Nl | Nl | Nl |
|
| |
Seborrheic dermatitis |
|
– | + | Any, onset during the 1st days or weeks of life | Greasy scaling on a yellow-red base | Scalp, axilla, and diaper area | – |
|
|||||||||||||
Psoriasis |
|
+ | + | Any, 2 peaks of onset 30-39 years and 50-59 years | Multiple | Well-circumscribed, pink papules and symmetrically distributed cutaneous plaques with silvery scales |
|
+ | + | +
Auspitz sign (pinpoint bleeding) |
_ | Nl | + |
|
|||||||
Lichen simplex [3]chronicus |
|
– | + | Any, peak at 30-50 years of age | Multiple | Lichenified and erythematous, pruritic exudative plaque, and excoriations | Scalp, head, neck, hands, arms, and genitals areas | – | + | – | – | Nl | – |
|
|
Nl | Nl | Nl |
|
| |
Ichthyosis vulgaris[4] |
|
+ | + | Usually in infancy | Multiple |
|
|
– | – | – | – | Nl | – |
|
|
Nl | Nl | Nl |
|
| |
Nummular dermatitis (discoid eczema) | Unknown | – | + | Any, two peaks, 6th-7th decade of life in males and 2nd-3rd decade of life in females | Multiple | Nl |
|
– | + | – | – | Nl | – |
|
|
Nl | Nl | Nl |
|
| |
Netherton's syndrome[5] | Autosomal recessive mutations in the serine protease inhibitor of Kazal type 5 gene (SPINK5), encoding LEKTI, a serine protease inhibitor | + | – | Affects neonates | Multiple |
|
|
+ | + | – | – | Nl | – |
|
|
|
Nl | Nl |
|
| |
Diseases | Etiology | Inherited | Acquired | Demography | Single/
Multiple |
Rash | Involved areas | Pustule | Itching | Bleeding | Fever | BP | Tenderness | Other | Associated factors | WBC | Platelets | ESR/CRP | Histopathology | Additional findings | |
Infection | Dermatophytes | ||||||||||||||||||||
Candida | |||||||||||||||||||||
Herpes simplex | |||||||||||||||||||||
Staphylococcus aureus | |||||||||||||||||||||
Molluscum contagiosum | Molluscum contagiosum virus inoculation through direct skin contact | – | + | Any, peak among children >5 years of age and young adults | Multiple |
|
|
– | + | – | – | Nl | – | If molluscum contagiosum is acquired as sexually transmitted disease, it involves, groin and genital region. |
|
Nl | Nl | Nl |
|
mMlluscum contagiosum
lesions on the eyelid may lead to follicular or papillary conjunctivitis . | |
Scabies | Multiple | Erythematous papular lesions | Flexor wrists, finger webs and genitalia | +++ |
|
||||||||||||||||
HIV | |||||||||||||||||||||
Diseases | Etiology | Inherited | Acquired | Demography | Single/
Multiple |
Rash | Involved areas | Pustule | Itching | Bleeding | Fever | BP | Tenderness | Other | Associated factors | WBC | Platelets | ESR/CRP | Histopathology | Additional findings | |
Immunologic disorders | Dermatitis herpetiformis[6] | Autoimmune disorder as a result of gluten sensitivity leading to the formation of IgA antibodies | – | + | Any, mean age of disease onset is 2nd-4th decade | Multiple |
|
|
– | + | – | – | Nl | – |
|
|
Nl | Nl | Nl |
|
|
Immune deficiency | Wiskott-Aldrich syndrome[7] |
|
+ | – | Seen almost exclusively in males in infancy | Multiple |
|
Rash can involve lesions located at the same areas of classical atopic dermatitis:
extensor surfaces of extremities and cheeks or scalp |
– | + | + | – | Nl | – | Infants can present with petechiae, prolonged bleeding from umbilicus or circumcision, purpura, hematemesis, melena, epistaxis, hematuria or unusal bruising |
|
|
Thrombocytopenia | Nl |
|
|
Hyper-IgE syndrome[8] |
|
+ | – | Rare, begin in infancy | Multiple |
|
|
+ | + | – | – | Nl | – |
|
|
|
Nl | Nl |
|
| |
DiGeorge syndrome | |||||||||||||||||||||
Severe combined immunodeficiency (SCID) | |||||||||||||||||||||
Ataxia telangiectasia | |||||||||||||||||||||
Diseases | Etiology | Inherited | Acquired | Demography | Single/
Multiple |
Rash | Involved areas | Pustule | Itching | Bleeding | Fever | BP | Tenderness | Other | Associated factors | WBC | Platelets | ESR/CRP | Histopathology | Additional findings | |
Metabolic Diseases | Phenylketonuria | ||||||||||||||||||||
Tyrosinemia | |||||||||||||||||||||
Histidinemia | |||||||||||||||||||||
Multiple carboxylase deficiency | |||||||||||||||||||||
Nutritional deficiencies | Zinc deficiency | ||||||||||||||||||||
Niacin (B3) deficiency | |||||||||||||||||||||
Pyridoxine (B6) deficiency | |||||||||||||||||||||
Biotin (B7) deficiency | |||||||||||||||||||||
Malignancy | Mycosis fungoides | Clonal expansion of CD4+ memory T cells (CD45RO+) | – | + | Mean age is 55- 60 years | Multiple | – | + | |||||||||||||
Histiocytosis X | |||||||||||||||||||||
Medications | Infliximab | ||||||||||||||||||||
Category | Diseases | Etiology | Inherited | Acquired | Demography | Single/
Multiple |
Rash | Involved areas | Pustule | Itching | Bleeding | Fever | BP | Tenderness | Other | Associated factors | WBC | Platelets | ESR/CRP | Histopathology | Additional findings |
References
- ↑ Nosbaum A, Vocanson M, Rozieres A, Hennino A, Nicolas JF (2009). "Allergic and irritant contact dermatitis". Eur J Dermatol. 19 (4): 325–32. doi:10.1684/ejd.2009.0686. PMID 19447733.
- ↑ Bains SN, Nash P, Fonacier L (October 2018). "Irritant Contact Dermatitis". Clin Rev Allergy Immunol. doi:10.1007/s12016-018-8713-0. PMID 30293200.
- ↑ Voicu C, Tebeica T, Zanardelli M, Mangarov H, Lotti T, Wollina U, Lotti J, França K, Batashki A, Tchernev G (July 2017). "Lichen Simplex Chronicus as an Essential Part of the Dermatologic Masquerade". Open Access Maced J Med Sci. 5 (4): 556–557. doi:10.3889/oamjms.2017.133. PMC 5535688. PMID 28785363.
- ↑ Thyssen JP, Godoy-Gijon E, Elias PM (June 2013). "Ichthyosis vulgaris: the filaggrin mutation disease". Br. J. Dermatol. 168 (6): 1155–66. doi:10.1111/bjd.12219. PMID 23301728.
- ↑ Chavanas S, Bodemer C, Rochat A, Hamel-Teillac D, Ali M, Irvine AD, Bonafé JL, Wilkinson J, Taïeb A, Barrandon Y, Harper JI, de Prost Y, Hovnanian A (June 2000). "Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome". Nat. Genet. 25 (2): 141–2. doi:10.1038/75977. PMID 10835624.
- ↑ Kárpáti S (2012). "Dermatitis herpetiformis". Clin. Dermatol. 30 (1): 56–9. doi:10.1016/j.clindermatol.2011.03.010. PMID 22137227.
- ↑ Buchbinder D, Nugent DJ, Fillipovich AH (2014). "Wiskott-Aldrich syndrome: diagnosis, current management, and emerging treatments". Appl Clin Genet. 7: 55–66. doi:10.2147/TACG.S58444. PMC 4012343. PMID 24817816.
- ↑ Mogensen TH (April 2013). "STAT3 and the Hyper-IgE syndrome: Clinical presentation, genetic origin, pathogenesis, novel findings and remaining uncertainties". JAKSTAT. 2 (2): e23435. doi:10.4161/jkst.23435. PMC 3710320. PMID 24058807.